This hypothesis is supported by the results of Niki et al. [36], who demonstrated that there were higher serum levels of COMP in patients with established RA and lower pre-treatment CRP levels than those in patients with early RA and elevated pre-treatment CRP levels. The gene discussed is COMP; the disease is rheumatoid arthritis.